ArticleInternational journal of clinical and experimental pathology2017
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients.Translational oncology · 2025Article
- TIMM8A-TIMM13 Complex Exerts Oncogenic Functions in Lung Cancer.Oncology research · 2025Article
- CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma.Frontiers in oncology · 2022Article
- Article
- The Association of microRNA-34a With High Incidence and Metastasis of Lung Cancer in Gejiu and Xuanwei Yunnan.Frontiers in oncology · 2021Article
- A comparison of mRNA and circRNA expression between squamous cell carcinoma and adenocarcinoma of the lungs.Genetics and molecular biology · 2020Article
- Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIt has been recently reported that cyclin-dependent kinase 6 (CDK6) is abnormally expressed in several human malignant tumors; however, CDK6 nuclear expression has not been fully studied in lung adenocarcinoma. We determined the correlation between the level of CDK6 expression and clinicopathologic data in lung adenocarcinoma patients, including survival. METHODS AND
resultsThe level of expression of CDK6 protein was detected by immunohistochemical analysis in 143 paraffin-embedded lung adenocarcinoma tissues and 35 normal paraffin-embedded lung tissues. The data showed that overexpression of nuclear CDK6 protein was present in lung adenocarcinoma. Further, we analyzed the correlation between the levels of nuclear CDK6 expression and clinical features, including survival prognosis. Higher expression of nuclear CDK6 protein was significantly associated with N stage (
conclusionsOur findings demonstrate that nuclear CDK6 protein is overexpressed and plays a detrimental role in disease progression and poor outcome with lung adenocarcinoma patients.
Indexed as
Identifiers
31966839PMC6965964W3026699364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.